Pfizer has welcomed a new R&D head, Chris Boshoff, who is expected to make significant strides in research and development to satisfy investors. Additionally, the biotech venture capital landscape is set to see some changes next year, with Atlas Venture partner Bruce Booth sharing insights on the industry’s annual review report and the potential impact of China and the new Trump administration on innovation.
Ned Sharpless, the former FDA commissioner, has taken on a new role at Jupiter Bioventures, while the search for his replacement at the FDA continues. Biotech enthusiasts can find more information on these developments and the top contenders for the FDA commissioner position.
Biotech journalist Adam Feuerstein and Allison DeAngelis are actively reporting on these exciting updates in the biotech and venture capital space. Feuerstein, a senior writer and biotech columnist, provides in-depth coverage of drug development, business, and biotechnology, and co-hosts The Readout Loud podcast. DeAngelis, the East Coast biotech and venture capital reporter at STAT, delves into the intersection of scientific ideas and financial investments.
For more details on these stories and the latest news in the life sciences industry, tune in to The Readout Loud podcast on Apple Podcasts, Spotify, Stitcher, TuneIn, or your preferred podcast platform. Stay informed about the evolving landscape of biotech, venture capital, and regulatory developments with expert analysis and insights from industry professionals.
